Format

Send to

Choose Destination
Inflamm Intest Dis. 2018 Mar;2(3):163-170. doi: 10.1159/000486131. Epub 2018 Jan 31.

Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).

Author information

1
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
2
Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
3
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
4
Division of Gastroenterology and Hepatology, Kantonsspital Luzern, Luzern, Switzerland.
5
Division of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
6
Division of Gastroenterology and Hepatology, Kantonsspital Fribourg, Fribourg, Switzerland.
7
Division of Gastroenterology and Hepatology, Inselspital and University of Bern, Bern, Switzerland.
8
GastroZentrum Netzer AG, Lindenhofspital, Bern, Switzerland.
9
Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland.
10
Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland.
11
Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
12
Crohn's and Colitis Center, La Source, Lausanne, Switzerland.
13
Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
14
Swiss EoE Clinic, Olten, Switzerland.

Abstract

Background and Aims:

The prospective, observational Swiss Eosinophilic Esophagitis Cohort Study (SEECS) was set up in 2015 with the following goals in mind: (1) to provide up-to-date epidemiologic data; (2) to assess the appropriateness of care; (3) to evaluate the psychosocial impact; and (4) to foster translational research projects. Data capture relies on validated instruments to assess disease activity and focuses on epidemiologic variables and biosamples (esophageal biopsies and blood specimens). An annual inclusion of 70 new patients with eosinophilic esophagitis (EoE) or proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is intended. We herein describe the SEECS cohort profile.

Methods:

The SEECS includes adult patients (age ≥18 years) with EoE or PPI-REE diagnosed according to published criteria. After inclusion, the patients are typically seen once a year for a clinical and endoscopic/histologic follow-up examination. Data are captured using validated questionnaires. Biosamples from patients with gastroesophageal reflux disease (GERD) and controls with a healthy esophagus are collected as well.

Results:

From January 2016 to July 2017, a total of 111 patients with EoE and 10 patients with PPI-REE were recruited. In addition, esophageal biopsies and blood samples from 11 patients with GERD and 20 controls with a healthy esophagus were collected. The mean age of the patients with EoE and those with PPI-REE was 39.6 ± 12.9 and 44.6 ± 15.6 years, respectively. A male predominance was found among both the patients with EoE (77.5%) and those with PPI-REE (70%). Concomitant allergic disorders were found in 79.3% of the patients with EoE and 90% of the patients with PPI-REE. At inclusion, the EoE patients were treated with the following therapeutic regimens: no therapy (0.9%), PPI (36%), swallowed topical corticosteroids (82.9%), elimination diets (15.3%), and esophageal dilation (19.8%).

Conclusions:

The SEECS is the first national cohort study of patients with EoE or PPI-REE. The SEECS will provide up-to-date epidemiologic data and foster translational research projects.

KEYWORDS:

Cohort profile; Cohort study; Eosinophilic esophagitis; Gastroesophageal reflux disease; Proton pump inhibitor-responsive esophageal eosinophilia

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center